ArticleThe Journal of clinical investigation2024

DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.

Zhen Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.